WO2012003814A1 - Composiciones vacunales a base de sticholisina encapsulada en liposomas - Google Patents
Composiciones vacunales a base de sticholisina encapsulada en liposomas Download PDFInfo
- Publication number
- WO2012003814A1 WO2012003814A1 PCT/CU2011/000004 CU2011000004W WO2012003814A1 WO 2012003814 A1 WO2012003814 A1 WO 2012003814A1 CU 2011000004 W CU2011000004 W CU 2011000004W WO 2012003814 A1 WO2012003814 A1 WO 2012003814A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- antigen
- liposomes
- vaccine vehicle
- protein
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000002502 liposome Substances 0.000 title abstract description 38
- 108091007433 antigens Proteins 0.000 claims abstract description 54
- 102000036639 antigens Human genes 0.000 claims abstract description 54
- 239000000427 antigen Substances 0.000 claims abstract description 49
- 150000002632 lipids Chemical class 0.000 claims abstract description 20
- 239000003053 toxin Substances 0.000 claims abstract description 19
- 231100000765 toxin Toxicity 0.000 claims abstract description 19
- 108700012359 toxins Proteins 0.000 claims abstract description 19
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims abstract description 18
- 230000028993 immune response Effects 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 230000024932 T cell mediated immunity Effects 0.000 claims description 5
- 238000005538 encapsulation Methods 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 241000242730 Stichodactyla helianthus Species 0.000 claims description 4
- 239000000568 immunological adjuvant Substances 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 241001083548 Anemone Species 0.000 claims 2
- 239000003981 vehicle Substances 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 13
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 4
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 238000007918 intramuscular administration Methods 0.000 abstract description 2
- 238000007920 subcutaneous administration Methods 0.000 abstract description 2
- 230000018044 dehydration Effects 0.000 abstract 1
- 238000006297 dehydration reaction Methods 0.000 abstract 1
- 210000004681 ovum Anatomy 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 239000012528 membrane Substances 0.000 description 15
- 239000013641 positive control Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 239000011148 porous material Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000000277 virosome Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 10
- 230000002949 hemolytic effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241000402062 Dolphin rhabdovirus Species 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000000539 dimer Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000002427 irreversible effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- PBFKSBAPGGMKKJ-UHFFFAOYSA-N 1-[6-(2,5-dioxopyrrolidin-1-yl)hexyl]pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1CCCCCCN1C(=O)CCC1=O PBFKSBAPGGMKKJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001571 immunoadjuvant effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000008823 permeabilization Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000242759 Actiniaria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000010156 Dunnett's T3 test Methods 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 241000877463 Lanio Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108091060736 actinoporin family Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Definitions
- the present invention relates to the field of Biotechnology applied to human health.
- the present invention relates to a vaccine vehicle for both subcutaneous and intramuscular use based on liposomes that contain sticholysin and that enhance a specific cellular immune response to antigens, useful in the immunotherapy of cancer and in the treatment of diseases caused by intracellular pathogens. .
- the immunoadjuvant capacity of liposomal vesicles has long been known.
- the rationality that exists in the use of liposomes in immunizations and in the design of vaccines is based on their ability to release the antigenic molecule in antigen presenting cells (APC) and stimulate an immune response.
- APC antigen presenting cells
- liposomes as immunoadjuvants are summarized in: (i) the ability to mimic pathogens by transporting large amounts of antigens to APCs, (ii) the possibility of co-encapsulating antigens together with immunostimulatory molecules, (iii) flexibility regarding the modification of its physicochemical properties with the purpose of greater effectiveness, and (iv) the fact of being biodegradable and non-toxic (Leserman in the Journal of Liposome Research, 2004, 14 (3 & 4), 175- 189).
- a challenge in the field of vaccinology is the potentiation of a cellular immune response mediated by cytotoxic CD8 + T lymphocytes (CTL) specific to antigens, with relevance for the prevention and treatment of diseases induced by intracellular pathogens and tumor cells.
- CTL cytotoxic CD8 + T lymphocytes
- Liposomal vesicles can potentiate a CTL response but not always effectively.
- Different strategies based on liposomal vesicles have been designed with the intention of making this function more efficient; Examples of this are liposomes sensitive to endosomal acidic pH, cationic liposomes, the inclusion of immunomodulators such as CpG and pore-forming toxins of bacterial origin.
- immunomodulators such as CpG and pore-forming toxins of bacterial origin.
- virosomes have not only been used as parental virus vaccines, but have also been exploited as vehicles for vaccine antigens, linked or encapsulated to the virosome (Zurbriggen in Vaccine, 2003 14; 21 (9-10): 921 - 4).
- Virosomal particles known by the acronym IRIV immunopotentiating reconstituted influenza virosomes
- IRIV immunopotentiating reconstituted influenza virosomes
- Immobilization of inactivated and highly pure hepatitis A viruses in the virosome membrane favored the processing and presentation of peptides derived by the classical MHCII pathway, as a result of the process of fusion of the virosomal and endosomal membranes in APCs (Glück and Wálti in Dev Biol (Basel), 2000, 103, 189-97).
- the evidence described indicates that the physical association of antigens-virosomes is important in immunoadjuvantity (Zurbriggen et al., Progr., In Lipid Res., 2000, 39 (1), 3-18; Amacker et al., In Int Immunol., 2005 , 17 (6), 695-704).
- Schumacher et al. In Vaccine 22: 714-723, 2004, reported that IRIVs are also capable of enhancing the cell-mediated immune response.
- Schumacher et al. Demonstrated their adjuvant activity in the induction of CTL in vitro. This ability depended mainly on the stimulation of the reactivity of specific CD4 + T cells to viral proteins.
- virosomes as an adjuvant has numerous advantages such as low toxicity and high immunogenicity
- one of the problems in current virosomal technology is the non-existence of procedures for efficient encapsulation of solutes, such as proteins, necessary for the induction of a CTL response to the lipid concentration at which virosomes are produced (approximately 1 mM of lipids), and given their diameter of approximately 200 nm, less than 1% of the aqueous phase is encapsulated within the virosomes (Schoen et al., in J. Liposome Res., 3: 767-792, 1993). These characteristics significantly reduce the efficiency of virosomes from releasing antigens or genes to cells.
- Sts are basic proteins with a high isoelectric point (> 9.5), with a molecular mass of approximately 20 kDa, lacking cysteine residues in their amino acid sequence and a preference for membranes containing sphingomyelin (SM). Sts are produced in soluble form but easily associated with different cell membrane systems and models forming pores with a diameter of 2 nm, probably due to the interaction of the ⁇ -helices of the N-terminal of four monomers. Both events, the association and the formation of the pore, depend on the physicochemical properties of the membranes.
- SM sphingomyelin
- the object of the present invention is a vaccine vehicle based on DPPC and Cho liposomal preparations in which the toxins known as Sts are co-encapsulated together with a protein antigen.
- They are also subject of the present invention are those of DPPC liposomal preparations and Cho in which co-encapsulated mutants of the toxins known as Sts (eg StlW111C and StlW111C ⁇ rev r) with the protein antigen.
- the vaccine compositions based on this vaccine vehicle and containing the toxins together with an antigen are also object of the present invention and are administered by the se or im route, for the induction of a potent CTL response specific to the antigen in question.
- a method for the treatment of a patient that requires a strengthening of his immune response the administration by the se or im route of vaccine compositions based on this vaccine vehicle and containing the Sts toxins is also the subject of the present invention. or its mutants together with an antigen relevant to the pathology.
- the present invention also relates to the protection provided by said vaccine compositions against challenge with tumor cells expressing the antigen, the percentage of tumor appearance is reduced and the survival of the carrier subjects is increased. Therefore, a prophylactic method for the onset of antigen-related disease is also the subject of the present invention.
- the vaccine vehicle object of the invention is based on aqueous dispersions of the DRPC liposomes of DPPC.Cho in a 1: 1 molar ratio that encapsulate St together with the antigen, and which may eventually contain other water-miscible co-solvents, not toxic, non-irritating and not causing destabilization of the vesicles, such as those commonly used in injectable pharmaceutical compositions, for example sugars, polyethylene glycol, etc.
- the liposomal preparations of the present invention are obtained by the dehydration-rehydration process and constituted by DPPC and Cho in a 1: 1 molar ratio and that co-encapsulate some of the variants of Sts or its reversibly inactive mutants together with an antigen ; wherein said vaccine compositions are capable of potentiating a CTL immune response specific to the antigen and protective against challenges with tumor cells.
- the vaccine composition comprises as an antigen the OVA protein, but where said antigen can be any protein or polypeptide associated with a pathology for which, from the therapeutic point of view, it is relevant to induce a specific CTL immune response against said protein antigen.
- the antigen could be a protein or polypeptide associated with cancer, a protein or polypeptide associated with AIDS or a protein or polypeptide associated with tuberculosis.
- the liposomes described in the present invention are obtained by dehydration-rehydration technology, described by Kirby and Gregoriadis in Biotechnology, 1984, 2, 979-984, these are vesicles with an internal aqueous phase surrounded by several lipid bilayers characterized by high efficiency of encapsulation and retention of labile molecules as antigens and immunomodulators of a protein nature.
- the chloroform solutions of DPPC and Cho in a 1: 1 molar ratio are broken and evaporated under vacuum for 30 minutes.
- the lipids are hydrated with deionized water at a temperature higher than the phase transition temperature (Te) of the DPPC (T> 45 ° C).
- MLVs multilamellar vesicle suspensions
- LUV Large Unilamellar Vesicles
- the vesicles obtained are mixed with the protein solutions, following a lipid ratio: protein of 16-64 ⁇ of lipids: 1.8 -7 nmol of antigen and 0.5-2 nmol of St and freeze-dried for 20-24 hours. Rehydration is performed with deionized water and stirring for 30 minutes at a temperature equal to or greater than 45 ° C.
- the non-encapsulated material in the liposomes is removed by washing with phosphate buffered saline (PBS) pH 7.4 (NaCl 136 mmol / l, KH2P04 1.47 mmol / l, Na2HP04 9.55 mmol / l, KCI 2.68 mmol / l) followed by centrifugation at 10,000 g for 15 minutes.
- PBS phosphate buffered saline
- Said preparations reach an encapsulation efficiency for the different variants of Sts that oscillates around 50% with a retention of 70% after a month of storage at 4 ° C in suspension in PBS.
- Stl and Stll toxins are isolated and purified from the sea anemone Stichodactyla helianthus, using the procedure described by Lanio et al., In Toxicon. 2001, 39, 187-94.
- the recombinant Sticholisin I (Stlr) and the Stlr mutant, Stl W111C, are obtained according to the procedures described by Pazos et al., In Toxicon, 2006, 48,1083-1094. and Pentón et al., (Press article), respectively.
- the concentration of Sts employed is in the range of 0.25-1 ⁇ and is co-encapsulated with the antigen in a concentration range of 1 - 3.5 ⁇ in a liposomal suspension with a range of Total lipid concentration of 16-64 mM.
- the vaccine vehicle of the present invention contains an amount of Sts of 0.3-4.4 nmol co-encapsulated with 1-2 nmol of the antigen in a liposomal suspension of 20 ymol of total lipids in a volume of
- the dose range used for the vaccines referred to in the present invention, by the se or im route, is between 1 nmol-2 nmol (50-100 g) of the antigen.
- An essential feature of the vaccine compositions object of the invention is that they lack other immunological adjuvants except those described.
- bacterial pore-forming toxins encapsulated in liposomal vesicles are capable of potentiating a CTL response, but the adverse effects of human use of vaccine compositions are known. based on toxins of bacterial origin; however, the authors of the present invention have unexpectedly found that non-bacterial toxins are capable of having the same immunostimulatory effect.
- the authors of this invention have succeeded in separating the pore-forming activity of toxins from their stimulatory effects of the CTL response, which offers great advantages for the clinical use in humans of this vaccine vehicle.
- the results obtained using the vaccine carrier of the present invention the molecular entities Stl W1 January 1 rre Cj vo Stll heat inactivated, co-encapsulated with the antigen in liposomes, to establish that there is no absolute dependence between the enhancing an CTL immune response specific to the antigen by the liposome-St formulations and the ability of these proteins to form pores in the membranes.
- the dendritic cell maturation (CDs) assay isolated from the bone marrow of C57BL / 6 mice and exposed to Stll in vitro, demonstrates the ability of this protein, not only in its active variant, but also in heat inactivated, of inducing the activation of the CDs, equivalent to that observed with the LPS (positive control) under similar conditions.
- Sts The ability of Sts to form pores in membranes was assessed by hemolytic activity and permeabilization assays of carboxifluorescein (CF) -LVVs as described by Mart ⁇ nez et al., In Toxicon, 2001, 39,1547-1560. It was shown that Sts do not exhibit permeabilizing activity by means of a permeabilization test of DPPC liposomal vesicles. Ch (1: 1) encapsulating CF, compared to that observed in vesicles constituted by egg yolk phosphatidyl choline and SM (1: 1 ) (Positive control).
- StlW111C mutant forms an inactive dimer stabilized by a disulfide bond by testing hemolytic activity and electrophoresis in PAGE-SDS in the presence and absence of 2-mercaptoethanol (2-ME) as a reducing agent, as described by Pentón and others, in Protein Eng Des Sel. 20 1, 24, 485-493.
- 2-ME 2-mercaptoethanol
- StlW111 C rr e V an irreversible dimeric species of StlW111C based on the reduction of StlW111C by incubation with 2-ME (0.1 mol / I), the elimination of this reducing agent by filtration on a PD-10 column and immediate incubation StlW111 Cmonómero with the homobifunctional reagent bis (maleimido) hexane (BMH) in a molar ratio StlW111C omero mon: BMH 1: 1 or 2: 1 for 2 hours at 4 ° C .
- StlW 11 Crev was purified by gel filtration chromatography on a Superdex 75 HR 10/30 column in the presence of a reducing agent.
- the immunomodulatory properties of the different Sts molecular species in the Liposome-St particulate system can be measured in the experimental mouse model of strain C57BL / 6 using the antigen and tumor line E.G7, a subclone of the murine thymoma EL-4 (Kusmartsev and Gabrilovich, in J Leukoc Biol., 2003, 74: 186-96), transfected with the complementary DNA of OVA pAc-neo-OVA (Moore, et al., In Cell, 1988, 54: 777-85) and obtained from the "American Type Cultures Collection" (ATCC, VA).
- ATCC American Type Cultures Collection
- Example 1 Cytotoxicity evaluation and CTL response of the vaccine vehicle using native Stl or STII and as an antigen the OVA protein.
- the liposome-based vaccine vehicle was prepared as previously described.
- DRVs vesicles composed of DPPC and Cho (1: 1 molar ratio) the OVA was co-encapsulated as a model antigen and Sts (Stl or Stll) in a ratio of 10 pmol of total lipids: 1.1 nmol OVA and 0.3 nmol of St in buffer saline phosphate (PBS) pH 7.4.
- PBS buffer saline phosphate
- Vaccine composition A DPPC DRVs liposomes: Cho (60 ⁇ of total lipids) encapsulating 6.6 nmol (50 ⁇ g) of OVA.
- Vaccine composition B DPPC.Cho DRVs liposomes (60 pmol of total lipids) that co-encapsulate 6.6 nmol (50 ⁇ g) OVA and 1.88 nmol of Stl or Stll.
- mice 15 female C57BL / 6 mice with a body weight of between 18-20 g were selected, and separated into 5 test groups of 3 animals each.
- Group 1 (negative control) was inoculated via, on days 0, 12, 13 and 14, with 0.2 ml of phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- Group 2 (positive control) was inoculated via, on day 12, with 22.2 nmoles (1 mg) of OVA and mixed with 100 pg of polyinosinoic-polycytidyl acid (PIC), a synthetic TLR3 ligand and a classical inducer of CTL response (Hamilton-Williams et al., in J. Immunol., 2005, 174: 1 159-63), on days 13 and 14 the animals again received 100 pg of PIC.
- PIC polyinosinoic-polycytidyl acid
- Group 3 was inoculated via the se, on days 0 and 12, with 0.2 ml of the vaccine composition A (equivalent to 1.1 nmol or 50 pg of OVA).
- Group 4 was inoculated subcutaneously, on days 0 and 12, with 0.2 ml of the vaccine composition B (equivalent to 1.1 nmol or 50 pg of OVA and 0.3 nmol or 6.25 pg of Stl).
- Group 5 was inoculated subcutaneously, on days 0 and 12, with 0.2 ml of the vaccine composition B (equivalent to 1.1 nmol or 50 pg of OVA and 0.3 nmol or 6.25 pg of Stll).
- spleen cells of unimmunized C57BIJ6 mice were incubated with two concentrations of carboxyfluorescein succinimidyl ester diacetate (CFSE) (0.33 and 5 ⁇ / ⁇ , respectively); Cells labeled with higher fluorescence intensity were also incubated with 1 ⁇ / ⁇ of the immunodominant OVA peptide (257-SIINFEKL-264) in the context of the MHC I haplotype of the C57BL / 6 mouse strain. Then, the labeled cells were mixed 1: 1 and the experimental groups 1-5 were inoculated by the tail vein with 30x10 6 cells of the mixture in a volume of 0.2 ml. Mice were sacrificed at 16 hours and the percentage of white cell lysis in the inguinal ganglion closest to the immunization site was determined by flow cytometry (FACS).
- FACS flow cytometry
- Figure 1 shows the cytotoxicity produced in vivo by immunization of mice with liposomes that co-encapsulated OVA and Sts.
- Animals immunized with liposomes encapsulating Sts (Stl or Stll) showed a response of specific cytotoxic CD8 + T lymphocytes (CTL) to OVA statistically superior to the positive control group.
- CTL cytotoxic CD8 + T lymphocytes
- liposomes containing only OVA also induced a CTL response statistically similar to the classic positive control of this assay (ICP).
- Example 2 Induction of antitumor protection of the vaccine vehicle in the OVA protein model.
- Liposome-based vaccines were studied for their ability to induce antitumor protection. For this, 60 female C57BL / 6 mice with a body weight between 18-20 g were selected, and separated into 3 test groups of 20 animals each.
- Group 1 (negative control) was inoculated intramuscularly, on days 0 and 12, with 0.2 ml of phosphate buffered saline (PBS).
- Group 2 was inoculated intramuscularly, on days 0 and 12, with 0.2 ml of the vaccine composition A described in example 1 (equivalent to 1.1 nmol or 50 pg of OVA).
- Group 3 was inoculated intramuscularly, on days 0 and 12, with 0.2 ml of the vaccine composition B described in example 1 (equivalent to 1.1 nmol or 50 g of OVA and 0.3 nmol or 6.25 pg of Stll).
- the animals were individualized from day 0 and the following parameters were determined three times per week: tumor volume, time to progression and survival.
- the time to progression is a parameter that assesses the time it takes for the tumor to appear in each individual animal, measured from the moment of inoculum. For mice that had not developed a tumor at the close of the experiment, the time to progression was considered to be 60 days. The impact on prolonging time to progression is a very desirable parameter for a cancer vaccine. As can be seen in Figure 2A, the animals of group 3, vaccinated with the vaccine composition formulation B described in Example 1 and object of the invention, showed the most relevant results.
- This parameter evaluates the ability of vaccination to increase the time that immunized animals live after the challenge with tumor cells expressing OVA (E.G7).
- the parameter is measured in days and has a relative character, since it is compared with the survival of untreated animals.
- the test of choice to see the statistical significance of survival comparisons is the Log-Rank.
- Figure 2B clearly shows that the animals of group 3, vaccinated with the vaccine composition B described in example 1 and object of the present invention, are the ones that survive the longest after inoculation of the tumor.
- Example 3 Hemolytic activity of the mimics of Sts.
- the formation of pores in the erythrocyte membrane generates a colloid-osmotic shock that results in cell lysis.
- the AH of the irreversibly inactive dimer of StlW1 1 1 C was compared with that of the reversible dimeric variant StlW1 1 1 C, under reducing conditions (2-ME 0.1 mol / l ) and non-reducing, for a relatively high concentration of proteins in the assay (0.15 pmol / l), when compared with the Stl / Stll AH reported by ⁇ lvarez et al., in Toxicon, 2009, 54 (8): 1135-47.
- the hemolysis kinetics shown in Figure 3 indicate that StlW11 C ir rev was inactive under non-reducing conditions. Under reducing conditions showed lower StlW111C ⁇ rr ev lytic activity StlW111C completely reduced and unreduced.
- Example 4 Evaluation of inactive Stll pore forming capacity.
- Example 5 Effect of the vaccine vehicle on the maturation of CDs.
- Stll-induced CD maturation was evaluated in cells obtained from the bone marrow of C57BL / 6 mice exposed to active Stll (0.1 nmole or 2 pg) or inactivated by heat treatment (4 pg) in the presence or absence of 20 pg of Polymyxin B (pmxB, neutralizing the biological activity of endotoxins by binding to the lipid portion A of the LPS), for 24 hours at 37 ° C in a chamber with 5% CO2.
- LPS (2 pg) was used as a positive control and RPMI plus pmxB as a negative negative control.
- the cells extracted from the bone marrow of the mouse were seeded in a number of 600,000 CD precursors in RPMI medium per well in 6-well plates.
- Figure 5 shows the percentage increase in molecular markers (CD80, CD86 and CD40) indicative of the activation of CDs as a result of the exposure of these cells in vitro to Stll, both in its active variant and inactivated by treatment. thermal and comparable to the results of the positive control.
- Example 6 Evaluation of cytotoxicity and CTL response of the vaccine vehicle using the St mutants and as an antigen the OVA protein.
- Vaccine composition A DPPC DRVs liposomes: Cho (60 pmol total lipids) encapsulating 6.6 nmol of OVA.
- Vaccine composition B DPPC DRVs liposomes: Cho (60 pmol of total lipids) that co-encapsulate 6.6 nmol of OVA and 1,875 nmol of St (StlW1 11 C, StlW1 Cirrev, native St II or Stll inactivated by heat treatment)
- Group 1 (negative control) was inoculated via, on days 0 and 12, with 0.2 ml of PBS.
- Group 2 (positive control) was inoculated via, on days 0 and 12, with 0.2 ml of the vaccine composition B (equivalent to 1.1 nmol or 50 pg of OVA and 0.3 nmol or 6.25 pg of Stll native)
- Group 3 was inoculated via, on days 0 and 12, with 0.2 ml of the vaccine composition B (equivalent to 1.1 nmol or 50 pg of OVA and 0.3 nmol or 6.25 pg of StlW1 1 1 C) .
- Group 4 was inoculated via, on days 0 and 12, with 0.2 ml of the vaccine composition B (equivalent to 1.1 nmol or 50 pg of OVA and 0.3 nmol or 6.25 pg of StlW11 1 C irrev ) .
- mice 9 female C57BLJ6 mice with a body weight between 8-20 g were selected, and separated into 3 test groups of 3 animals each.
- Group 1 (negative control) was inoculated via, on days 0 and 12, with 0.2 ml of phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- Group 2 was inoculated subcutaneously, on days 0 and 12, with 0.2 ml of the vaccine composition A (equivalent to 1.1 nmol or 50 pg of OVA).
- Group 3 was inoculated subcutaneously, on days 0 and 12, with 0.2 ml of the vaccine composition B (equivalent to 1.1 nmol or 50 pg of OVA and 0.3 nmol or 6.25 pg of inactive Stll).
- Figure 6B shows that immunization with liposomes that co-encapsulate OVA and the Stll variant completely inactivated by heat treatment generated an OVA-specific cytotoxic activity significantly higher than that induced by liposomes that only contained the antigen and similar to that observed with the Liposomal formulation containing native Stl / Stll.
- Figure 1 represents a graph with the percentage of lysis of the white cells loaded with the immunodominant peptide of OVA (SIINFEKL) and labeled with CFSE in experimental animals subjected to different vaccine treatments in an in vivo cytotoxicity test. Each point corresponds to the data of an animal and the line to the average value of at least two independent experiments. The different letters indicate statistical significance among the groups immunized according to the Dunnett T3 test (p ⁇ 0.05).
- Figure 2A represents the percentage of animals without tumor in three groups of experimental animals subjected to different vaccine treatments and challenged with tumor cells expressing OVA.
- Figure 2B represents a graph that allows the survival parameter after inoculation of tumor cells expressing OVA to be appreciated in the 3 groups mentioned. Different letters indicate statistical significance according to the Log-Rank test (p ⁇ 0.05).
- Figure 3 shows the variation in turbidity of an erythrocyte suspension product of the action of the dimeric variants of Stl (StlW111C or StlW111 Crerv) under reducing conditions (presence of 2-ME) and non-reducing.
- Figure 4 represents the loss of turbidity of an erythrocyte suspension due to the action of native Stll (active protein) or inactivated by heat treatment.
- FIG. 5 shows the variation in the expression of molecular markers in dendritic cells (CDs) by in vitro exposure to St II in its active and inactivated variants by heat treatment in the presence or absence of an endotoxin neutralizer (pmxB).
- Figure 6 represents two graphs with the percentage of lysis of white cells loaded with the immunodominant OVA peptide (SIINFEKL) and labeled with CFSE in experimental animals subjected to different vaccine treatments in an in vivo cytotoxicity test. Each point corresponds to the data of an animal and the line to the average value. The different letters indicate statistical significance among the groups immunized according to the Tukey test (p ⁇ 0.05).
- Graph A Response obtained by immunization with liposomes that co-encapsulate OVA, native Stll or dimeric variants of reversible Stl (StlW111C) or irreversibly (StlW111 C irr and V ) inactive.
- Graph B Response obtained by immunization with liposomes that co-encapsulate OVA and Stll inactivated by heat treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201301383A UA111944C2 (uk) | 2010-07-06 | 2011-05-07 | Вакцинна композиція на основі стихолізину, інкапсульованого в ліпосоми |
CA2802443A CA2802443C (en) | 2010-07-06 | 2011-07-05 | Vaccine compositions based on sticholysin encapsulated in liposomes |
SG2013000690A SG186931A1 (en) | 2010-07-06 | 2011-07-05 | Vaccine compositions based on sticholysin encapsulated in liposomes |
EA201291449A EA025333B1 (ru) | 2010-07-06 | 2011-07-05 | Вакцинный носитель для индукции клеточного иммунного ответа |
MYPI2013000019A MY167896A (en) | 2010-07-06 | 2011-07-05 | Vaccine composition based on sticholysin encapsulated into liposomes. |
BR112012033284-8A BR112012033284B1 (pt) | 2010-07-06 | 2011-07-05 | veículo vacinal para induzir resposta imune celular, e, composição vacinal |
JP2013517001A JP5685646B2 (ja) | 2010-07-06 | 2011-07-05 | リポソーム中にカプセル化されたスチコリシンに基づくワクチン組成物 |
AU2011276812A AU2011276812B2 (en) | 2010-07-06 | 2011-07-05 | Vaccine compositions based on sticholysin encapsulated in liposomes |
MX2012015173A MX2012015173A (es) | 2010-07-06 | 2011-07-05 | Composiciones vacunales a base de sticholisina encapsulada en liposomas. |
US13/808,276 US8697093B2 (en) | 2010-07-06 | 2011-07-05 | Vaccine composition based on sticholysin encapsulated into liposomes |
ES11743950.5T ES2576851T3 (es) | 2010-07-06 | 2011-07-05 | Composiciones vacunales a base de sticholisina encapsuladas en llposomas |
EP11743950.5A EP2591802B1 (en) | 2010-07-06 | 2011-07-05 | Vaccine compositions based on sticholysin encapsulated in liposomes |
KR1020137000208A KR101455055B1 (ko) | 2010-07-06 | 2011-07-05 | 리포솜으로 캡슐화된 스티코리신에 따른 백신 조성물 |
CN201180033067.XA CN102971011B (zh) | 2010-07-06 | 2011-07-05 | 基于包囊在脂质体中的海葵溶细胞素的疫苗组合物 |
TNP2012000592A TN2012000592A1 (en) | 2010-07-06 | 2012-12-13 | Vaccine compositions based on sticholysin encapsulated in liposomes |
ZA2013/00059A ZA201300059B (en) | 2010-07-06 | 2013-01-03 | Vaccine compositions based on sticholysin encapsulated in liposomes |
HK13104046.1A HK1177138A1 (en) | 2010-07-06 | 2013-04-02 | Vaccine compositions based on sticholysin encapsulated in liposomes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20100144A CU20100144A7 (es) | 2010-07-06 | 2010-07-06 | Composiciones vacunales a base de sticholisina encapsulada en liposomas |
CUCU/P/2010/144 | 2010-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012003814A1 true WO2012003814A1 (es) | 2012-01-12 |
Family
ID=44533576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2011/000004 WO2012003814A1 (es) | 2010-07-06 | 2011-07-05 | Composiciones vacunales a base de sticholisina encapsulada en liposomas |
Country Status (24)
Country | Link |
---|---|
US (1) | US8697093B2 (es) |
EP (1) | EP2591802B1 (es) |
JP (1) | JP5685646B2 (es) |
KR (1) | KR101455055B1 (es) |
CN (1) | CN102971011B (es) |
AR (1) | AR081661A1 (es) |
AU (1) | AU2011276812B2 (es) |
BR (1) | BR112012033284B1 (es) |
CA (1) | CA2802443C (es) |
CL (1) | CL2012003674A1 (es) |
CO (1) | CO6640312A2 (es) |
CU (1) | CU20100144A7 (es) |
EA (1) | EA025333B1 (es) |
ES (1) | ES2576851T3 (es) |
HK (1) | HK1177138A1 (es) |
MX (1) | MX2012015173A (es) |
MY (1) | MY167896A (es) |
PE (1) | PE20130390A1 (es) |
SG (1) | SG186931A1 (es) |
TN (1) | TN2012000592A1 (es) |
TW (1) | TWI457145B (es) |
UA (1) | UA111944C2 (es) |
WO (1) | WO2012003814A1 (es) |
ZA (1) | ZA201300059B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014034669A1 (ja) * | 2012-08-28 | 2014-03-06 | 国立大学法人北海道大学 | 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102069670B1 (ko) * | 2017-03-02 | 2020-01-23 | 단디바이오사이언스 주식회사 | 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
EP3651733A4 (en) * | 2017-07-10 | 2021-04-07 | ImmunoVaccine Technologies Inc. | PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING USING LIPID VESICLE PARTICLES OF DEFINED SIZE, AND USES THEREOF |
CN113041346A (zh) * | 2019-12-26 | 2021-06-29 | 复旦大学 | 一种细菌毒素疫苗及其在预防细菌感染中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565203A (en) | 1991-05-08 | 1996-10-15 | Schweiz. Serum- & Impfinstitut Bern | Hepatitis A virus in a reconstituted influenza virosome and use as a vaccine |
US20100015214A1 (en) | 2005-12-16 | 2010-01-21 | Pevion Biotech Ltd. | Novel Trans-Adjuvant System |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
AU2006351536B2 (en) | 2006-12-04 | 2011-11-24 | National Agriculture And Food Research Organization | Method for producing biomineral-containing substance and organic hydroponics method |
-
2010
- 2010-07-06 CU CU20100144A patent/CU20100144A7/es unknown
-
2011
- 2011-05-07 UA UAA201301383A patent/UA111944C2/uk unknown
- 2011-06-24 AR ARP110102211A patent/AR081661A1/es not_active Application Discontinuation
- 2011-06-29 TW TW100122821A patent/TWI457145B/zh active
- 2011-07-05 MY MYPI2013000019A patent/MY167896A/en unknown
- 2011-07-05 AU AU2011276812A patent/AU2011276812B2/en active Active
- 2011-07-05 PE PE2013000004A patent/PE20130390A1/es not_active Application Discontinuation
- 2011-07-05 CN CN201180033067.XA patent/CN102971011B/zh active Active
- 2011-07-05 EA EA201291449A patent/EA025333B1/ru not_active IP Right Cessation
- 2011-07-05 BR BR112012033284-8A patent/BR112012033284B1/pt not_active IP Right Cessation
- 2011-07-05 ES ES11743950.5T patent/ES2576851T3/es active Active
- 2011-07-05 US US13/808,276 patent/US8697093B2/en active Active
- 2011-07-05 KR KR1020137000208A patent/KR101455055B1/ko active IP Right Grant
- 2011-07-05 JP JP2013517001A patent/JP5685646B2/ja active Active
- 2011-07-05 MX MX2012015173A patent/MX2012015173A/es active IP Right Grant
- 2011-07-05 CA CA2802443A patent/CA2802443C/en active Active
- 2011-07-05 SG SG2013000690A patent/SG186931A1/en unknown
- 2011-07-05 WO PCT/CU2011/000004 patent/WO2012003814A1/es active Application Filing
- 2011-07-05 EP EP11743950.5A patent/EP2591802B1/en active Active
-
2012
- 2012-12-13 TN TNP2012000592A patent/TN2012000592A1/en unknown
- 2012-12-18 CO CO12229159A patent/CO6640312A2/es unknown
- 2012-12-21 CL CL2012003674A patent/CL2012003674A1/es unknown
-
2013
- 2013-01-03 ZA ZA2013/00059A patent/ZA201300059B/en unknown
- 2013-04-02 HK HK13104046.1A patent/HK1177138A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565203A (en) | 1991-05-08 | 1996-10-15 | Schweiz. Serum- & Impfinstitut Bern | Hepatitis A virus in a reconstituted influenza virosome and use as a vaccine |
US20100015214A1 (en) | 2005-12-16 | 2010-01-21 | Pevion Biotech Ltd. | Novel Trans-Adjuvant System |
Non-Patent Citations (26)
Title |
---|
ALVAREZ CARLOS ET AL: "Sticholysins, two pore-forming toxins produced by the Caribbean Sea anemone Stichodactyla helianthus: their interaction with membranes.", TOXICON : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY ON TOXINOLOGY 15 DEC 2009 LNKD- PUBMED:19268489, vol. 54, no. 8, 15 December 2009 (2009-12-15), pages 1135 - 1147, XP002660719, ISSN: 1879-3150 * |
ALVAREZ ET AL., TOXICON, vol. 54, no. 8, 2009, pages 1135 - 47 |
AMACKER ET AL., INT IMMUNOL., vol. 17, no. 6, 2005, pages 695 - 704 |
DIETRICH G ET AL: "From evil to good: a cytolysin in vaccine development", TRENDS IN MICROBIOLOGY, ELSEVIER SCIENCE LTD., KIDLINGTON, GB, vol. 9, no. 1, 1 January 2001 (2001-01-01), pages 23 - 28, XP002382792, ISSN: 0966-842X, DOI: 10.1016/S0966-842X(00)01893-X * |
DIETRICH, MORON ET AL., TRENDS IN MICROBIOLOGY, vol. 9, no. 1, 2001, pages 23 - 28 |
GLUCK Y VVAITI, DEV BIOL (BASEL, vol. 103, 2000, pages 189 - 97 |
HAMILTON-WILLIAMS ET AL., J. IMMUNOL., vol. 174, 2005, pages 1159 - 63 |
KIRBY, GREGORIADIS, BIOTECHNOLOGY, vol. 2, 1984, pages 979 - 984 |
KUSMARTSEV Y GABRILOVICH, J LEUKOC BIOL., vol. 74, 2003, pages 186 - 96 |
LANIO ET AL., J LIPOSOME RES., vol. 18, no. 1, 2008, pages 1 - 19 |
LANIO ET AL., TOXICON, vol. 39, 2001, pages 187 - 94 |
LANIO M E ET AL: "Humoral immune response against epidermal growth factor encapsulated in dehydration rehydration vesicles of different phospholipid composition.", JOURNAL OF LIPOSOME RESEARCH 2008 LNKD- PUBMED:18348068, vol. 18, no. 1, 2008, pages 1 - 19, XP022350779, ISSN: 1532-2394 * |
LESERMAN, JOURNAL OF LIPOSOME RESEARCH, vol. 14, no. 3, 4, 2004, pages 175 - 189 |
MARTINEZ ET AL., JOURNAL BIOLOGY, vol. 16, no. 2, 2002, pages 85 - 93 |
MARTINEZ ET AL., TOXICON, vol. 39, 2001, pages 1547 - 1560 |
MARTINEZ ET AL: "Effect of sphingomyelin and cholesterol on the interaction of St II with lipidic interfaces", TOXICON, ELMSFORD, NY, US, vol. 49, no. 1, 15 December 2006 (2006-12-15), pages 68 - 81, XP005803971, ISSN: 0041-0101, DOI: 10.1016/J.TOXICON.2006.09.019 * |
MARTINEZ, TOXICON, vol. 49, 2007, pages 68 - 81 |
MOORE ET AL., CELL, vol. 54, 1988, pages 777 - 85 |
PAZOS ET AL., TOXICON, vol. 48, 2006, pages 1083 - 1094 |
PENT6N ET AL., PROTEIN ENG DES SEL, vol. 24, 2011, pages 485 - 493 |
PENTON ET AL., PROTEIN ENG DES SEL., vol. 24, 2011, pages 485 - 493 |
SCHOEN ET AL., J., LIPOSOME RES., vol. 3, 1993, pages 767 - 792 |
SCHUMACHER ET AL., VACCINE, vol. 22, 2004, pages 714 - 723 |
TRENDS IN IMMUNOLOGY, vol. 25, no. 2, 2004, pages 92 - 97 |
ZURBRIGGEN ET AL., PROGR., IN LIPID RES., vol. 39, no. 1, 2000, pages 3 - 18 |
ZURBRIGGEN, VACCINE, vol. 21, no. 9-10, 14 December 2002 (2002-12-14), pages 921 - 4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014034669A1 (ja) * | 2012-08-28 | 2014-03-06 | 国立大学法人北海道大学 | 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法 |
JPWO2014034669A1 (ja) * | 2012-08-28 | 2016-08-08 | 国立大学法人北海道大学 | 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法 |
US9717687B2 (en) | 2012-08-28 | 2017-08-01 | National University Corporation Hokkaido University | Lipid membrane structure including bacterial cell component having dispersibility in non-polar solvent, and method for producing same |
Also Published As
Publication number | Publication date |
---|---|
ZA201300059B (en) | 2013-09-25 |
CA2802443A1 (en) | 2012-01-12 |
ES2576851T3 (es) | 2016-07-11 |
TW201217000A (en) | 2012-05-01 |
EP2591802A1 (en) | 2013-05-15 |
SG186931A1 (en) | 2013-02-28 |
AR081661A1 (es) | 2012-10-10 |
BR112012033284A2 (pt) | 2017-05-02 |
EA025333B1 (ru) | 2016-12-30 |
TN2012000592A1 (en) | 2014-04-01 |
AU2011276812A1 (en) | 2013-01-10 |
CU20100144A7 (es) | 2012-06-21 |
JP5685646B2 (ja) | 2015-03-18 |
AU2011276812B2 (en) | 2013-12-19 |
KR20130027547A (ko) | 2013-03-15 |
CO6640312A2 (es) | 2013-03-22 |
BR112012033284B1 (pt) | 2021-05-18 |
CN102971011A (zh) | 2013-03-13 |
US20130149376A1 (en) | 2013-06-13 |
EP2591802B1 (en) | 2016-06-08 |
EA201291449A1 (ru) | 2013-05-30 |
KR101455055B1 (ko) | 2014-10-28 |
CA2802443C (en) | 2015-03-17 |
CN102971011B (zh) | 2014-12-03 |
MY167896A (en) | 2018-09-26 |
UA111944C2 (uk) | 2016-07-11 |
CL2012003674A1 (es) | 2013-07-12 |
US8697093B2 (en) | 2014-04-15 |
TWI457145B (zh) | 2014-10-21 |
PE20130390A1 (es) | 2013-04-11 |
JP2013530190A (ja) | 2013-07-25 |
MX2012015173A (es) | 2013-02-11 |
HK1177138A1 (en) | 2013-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6625587B2 (ja) | Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 | |
ES2524699T3 (es) | Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba | |
AU731705B2 (en) | Liposomal influenza vaccine composition and method | |
AU2008307042B2 (en) | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof | |
AU2002311616B2 (en) | A method for preparation of vesicles loaded with biological material and different uses thereof | |
IL175573A (en) | Pharmaceutical compositions comprising vaccine antigen(s) other than a coding dna and phosphoric ester derivative(s) of phosphatidylcholine and their use for preparing a vaccine adjuvant | |
ES2576851T3 (es) | Composiciones vacunales a base de sticholisina encapsuladas en llposomas | |
ES2389061T3 (es) | Un sistema adyuvante que comprende virosomas y liposomas | |
ES2424131T3 (es) | Vacuna para modular respuestas inmunitarias entre T1 y T2 | |
US7538083B2 (en) | Compositions and methods for the potentiation of immune responses against target antigens | |
Gregoriadis | Liposomes as immunological adjuvants for peptide and protein antigens | |
Singh et al. | Vesicular systems for non-invasive topical immunization: rationale and prospects | |
US20100209452A1 (en) | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof | |
WO2003000232A2 (en) | Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides | |
Freitas et al. | The Use of Liposomes as Snake Venom Vehicles. Application in Protective Immunization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180033067.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11743950 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2802443 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12229159 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/015173 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012003674 Country of ref document: CL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201291449 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2013517001 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000004-2013 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: 20137000208 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013500036 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011276812 Country of ref document: AU Date of ref document: 20110705 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011743950 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201301383 Country of ref document: UA Ref document number: 13808276 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012033284 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012033284 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121226 |